USTEKINUMAB

Information current as at: 1 August 2025

The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.


Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Epyztek®
Pharmaceutical company:
SAMSUNG BIOEPIS AU PTY LTD
Condition/indication:
(therapeutic use)
  • Severe chronic plaque psoriasis Severe psoriatic arthritis Severe Crohn disease Complex refractory fistulising Crohn disease
PBAC Submission type:
New PBS listing (Category 3)
Comment:
--
Related medicines:
--

Progress Details

Submission received for:
March 2025 PBAC meeting
Opportunity for consumer comment:
Open 27/11/2024 and close 29/01/2025 (see PBS Website)
PBAC meeting:
Held on 12/03/2025
4PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
Awaiting lodgement from pharmaceutical company
5Lodgement of required documentation:
Has not yet commenced
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred

Case ID: a1002

Page last updated: 31 July 2025

v.9.18